Navigation Links
Timothy I. Still Appointed as President and CEO of Myoscience
Date:10/1/2018

Myoscience, Inc. announced today the appointment of Timothy I. Still as its new President and Chief Executive Officer. Mr. Still will also be joining the Company’s Board of Directors.

Mr. Still’s background includes over 28 years of experience in medical devices and diagnostics. He has extensive leadership experience in designing and implementing highly focused commercial and business development strategies within both small and large companies. Mr. Still has been directly responsible for building the commercial viability at many of his previous companies, four of which have been successfully acquired.

Most recently, Mr. Still was the Executive Chairman of Gold Standard Diagnostics. He served on the company’s Board for over four years; and subsequently took on a more active role resulting in the sale of the company to Eurofins in July of 2018. Prior appointments include CEO roles at Global Kinetics Corporation, Xagenic and Accumetrics. Mr. Still has also held executive positions at HemoSense, Cholestech Corporation and Boehringer Mannheim Corporation. He received a B.S. degree (with Honors) in Biological Sciences from the University of California at Davis, and an MBA (Deans Scholar) in Marketing and Entrepreneurship from the University of Southern California.

“I am honored to be given the opportunity to lead Myoscience at this exciting time in the company’s history. With its vast market opportunity, patented technology, increasing commercial adoption and product development pathway, Myoscience is positioned for tremendous success” said Mr. Still.

Brian Farley, Chairman of the Board at Myoscience commented, “We are very pleased to welcome an executive with the leadership and track record of Timothy Still. With his experience in the commercialization of innovative medical technologies, we believe that Tim’s strong operational and business development skills will be instrumental at helping Myoscience successfully execute our strategy of delivering our iovera® pain management solution for the millions of patients with painful conditions, particularly those with osteoarthritis of the knee or who undergo knee replacement surgery.

The board would also like to thank Edward Kleinhans for his leadership during the last five months as Interim Chief Executive Officer at Myoscience.

For additional information, please visit http://www.iovera.com or email us directly at mediarelations@myoscience.com.

ABOUT MYOSCIENCE
Silicon Valley, California-based Myoscience is a privately-held medical device company committed to making its platform technology, the iovera° system, the standard of care for the treatment of peripheral nerves. The iovera° treatment is powered by a patented miniaturization of traditional cryotherapy. The ioveraº system is 510k cleared in the U.S. for the blocking of pain, the relief of pain and symptoms associated with osteoarthritis of the knee for up to 90 days and general surgical use. For more information, please visit http://www.iovera.com.

© 2018 Myoscience. All rights reserved. iovera° is a trademark of Myoscience. MKT-0521 REV A

Read the full story at https://www.prweb.com/releases/timothy_i_still_appointed_as_president_and_ceo_of_myoscience/prweb15802302.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Binary Biometrics, Founded by James Timothy White, Expands Services to 13+ Locations With the Addition of Owner/Operator Kevin Morris
2. Rett Syndrome Research Trust Names Timothy A. Riley Chief Scientific Officer and Chief Business Officer; Randall Carpenter Transitions to Chief Medical Officer
3. Nutritional quality at fast-food restaurants still needs improvement
4. Recovery of Hawaiian green sea turtles still short of historic levels, Stanford-led study suggests
5. ACS podcast: Many people still lack access to flush toilets, adequate sanitation
6. Seafood still considered a good source of nutrients but consumers confused on safety
7. Heavily logged forests still valuable for tropical wildlife
8. Bed bugs can survive freezing temperatures, but cold can still kill them
9. The science of baby-making still a mystery for many women
10. U of T report finds millions of Canadians still struggle to afford food
11. Still-fresh remnants of Exxon Valdez oil protected by boulders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2019)... ... 2019 , ... At their May 16 meeting, the members of the F04.43 ... the American Society for Testing and Materials International voted unanimously to approve ... next step in the company’s plan to establish its AlphaSTEM Test™ stem ...
(Date:5/14/2019)... ... May 14, 2019 , ... IMMUNE 3D®, ... beyond immuno-oncology into areas of autoimmunity, fibrosis and skin immunology. In addition, the ... lines for IO discovery efforts. , IMMUNE 3D®’s proprietary platform aims to ...
(Date:5/8/2019)... , ... May 07, 2019 ... ... has been accepted into Forbes Technology Council, an invitation-only community for world-class ... Company, is a full-service biopharmaceutical cold chain engineering firm that guarantees confidence ...
Breaking Biology News(10 mins):
(Date:5/21/2019)... ... May 21, 2019 , ... DuPont ... officially opened the inaugural Africa Brewing Conference dedicated to sharing brewing knowledge, strengthening ... The event, which is supported through a partnership with “Ethiopia Invest”, will run ...
(Date:5/14/2019)... ... May 14, 2019 , ... Gateway Genomics , ... doubling its space from 2,500 to 5,000 square feet. , “This past year ... tests ,” says Gateway Genomics CEO, Chris Jacob. “The SneakPeek At-Home test, which is ...
(Date:5/4/2019)... ... May 03, 2019 , ... Diopsys Inc, the world ... Negative Response vision test, a new full field electroretinography (ffERG) protocol designed ... 6.3 million Americans will have glaucoma, with black Americans having the highest prevalence ...
(Date:5/2/2019)... VIEJO, Calif. (PRWEB) , ... May 02, 2019 ... ... leading clinical genetics testing company, will present results documenting discrepancies between U.S. insurer ... management guidelines for patients at risk for hereditary breast and ovarian cancer (HBOC). ...
Breaking Biology Technology: